Patents by Inventor Thungathurthi Srinivasa Rao

Thungathurthi Srinivasa Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic form of imatinib mesylate and a process for its preparation
    Patent number: 8048883
    Abstract: This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as ?2 Form, which is stable at room temperature and even at higher temperatures up to 120° C. and accelerated stress conditions and, freely soluble in water. This invention also discloses a pharmaceutical composition containing the novel stable ?2 form of Imatinib mesylate and other usually employed excipients, useful in the treatment of Chronic Myelogenous Leukemia (CML). This new ?2 Form of imatinib mesylate is prepared by slurrying Imatinib base in isopropanol at room temperature followed by addition of methane sulfonic acid and maintaining 50-60 ° C. followed by filtration. This invention also discloses another process for the preparation of the novel, stable ?2 crystalline form of Imatinib Mesylate by the conversion of Imatinib mesylate ?-polymorphic modification by suspending it in water and organic solvents, distilling off water azeotropically, cooling and filtering to obtain the ?2 crystal form.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: November 1, 2011
    Assignee: Natco Pharma Limited
    Inventors: Kompella Amala, Thungathurthi Srinivasa Rao, Bhujanga rao Adibhatla Kali Satya, Sreenivas Rachakonda, Nannapaneni Venkaiah Chowdary, Khadgapathi Podili
  • Novel Polymorphic Form Of Imatinib Mesylate And A Process For Its Preparation
    Publication number: 20080255138
    Abstract: This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as ?2 Form, which is stable at room temperature and even at higher temperatures up to 120° C. and accelerated stress conditions and, freely soluble in water. This invention also discloses a pharmaceutical composition containing the novel stable ?2 form of Imatinib mesylate and other usually employed excipients, useful in the treatment of Chronic Myelogenous Leukemia (CML). This new ?2 Form of imatinib mesylate is prepared by slurrying Imatinib base in isopropanol at room temperature followed by addition of methane sulfonic acid and maintaining 50-60 ° C. followed by filtration. This invention also discloses another process for the preparation of the novel, stable ?2 crystalline form of Imatinib Mesylate by the conversion of Imatinib mesylate ?-polymorphic modification by suspending it in water and organic solvents, distilling off water azeotropically, cooling and filtering to obtain the ?2 crystal form.
    Type: Application
    Filed: November 16, 2004
    Publication date: October 16, 2008
    Applicant: Natco Pharma Limited
    Inventors: Kompella Amala, Thungathurthi Srinivasa Rao, Bhujanga rao Adibhatla Kali Satya, Sreenivas Rachakonda, Nannapaneni Venkaiah Chowdary, Khadgapathi Podili